AVRX Avalon Pharmaceuticals (MM)

Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced that Kenneth C. Carter, Ph.D., President and CEO, will provide an update on the Company at the BIO CEO & Investor Conference. The conference will be held at the Waldorf-Astoria Hotel in New York from February 11-13. Dr. Carter is scheduled to present on Monday, February 11, at 3:30pm. The presentation will be available live via webcast and can be accessed through the Investor Presentations section of Avalon Pharmaceuticals� website, http://www.avalonrx.com, or go directly to the webcast via the following URL: http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=AVRX&item_ id=1752233. (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.) An archive of the presentation will be available for 90 days following the conference. About Avalon Pharmaceuticals Avalon is a biopharmaceutical company focused on the discovery, development and commercialization of first-in-class cancer therapeutics. Avalon�s lead product candidate, AVN944,�an IMPDH inhibitor, is in Phase II clinical development. Avalon also has preclinical programs to develop inhibitors of the Beta-catenin and Aurora/Centrosome pathways,�discovery programs�for�inhibitors of�the Survivin�and Myc�pathways and partnerships with Merck, MedImmune, ChemDiv, Medarex, and Novartis. AvalonRx� is the company�s proprietary platform�which is based on�large-scale�biomarker identification and monitoring, used to discover and develop therapeutics for pathways that have historically been characterized as "undruggable." Avalon is headquartered in Germantown, MD. Safe Harbor Statement This announcement contains, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect the current views of Avalon management and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, risks and uncertainties, including those specified under the �Risk Factors� section of our 2006 Annual Report on Form 10-K and updates contained in subsequent filings we make with the Securities and Exchange Commission.